Arrowhead Pharma Jumps 21% After Plozasiran Trial Cuts Triglycerides, Lifting Target to $115
Updated
Updated · pluang.com · Jul 22
Arrowhead Pharma Jumps 21% After Plozasiran Trial Cuts Triglycerides, Lifting Target to $115
3 articles · Updated · pluang.com · Jul 22
Summary
Arrowhead shares surged more than 21% after late-stage data showed plozasiran significantly reduced triglyceride levels in patients with severe hypertriglyceridemia.
Chardan Capital responded by raising its price target to $115, signaling stronger expectations for the drug after the trial win.
Plozasiran’s success strengthens Arrowhead’s position in the severe hypertriglyceridemia market, where the result also pressured rival Ionis Pharmaceuticals’ shares.
The move highlights how a single positive Phase 3-style readout can quickly reshape biotech valuations and competitive expectations.